Loading
A phase 3 trial testing Vepugratinib in bladder & urothelial cancer, now recruiting.
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract is a phase 3 interventional study registered as NCT07218380, led by Eli Lilly and, and recruiting on the registry. Official title: FORAGER-2: A Phase 3, Randomised, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined With Enfortumab Vedotin and Pembrolizumab in Adults With Untreated Locally Advanced or Metastatic Urothelial Carcinoma With an FGFR3 Genetic Alteration. Planned enrolment is 450 participants (estimated). The study started in 2025-12-12 and primary completion is expected in 2029-10. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer.
Shares Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer.
Shares Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer.
Shares Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer.
Shares Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer.
Shares Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer.
Shares Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer.
Shares Muscle-invasive and advanced bladder cancer, Bladder & urothelial cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/